FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis

Science

Volumn 279, Issue 5358, 1998, Pages 1954-1958

  Yeh, Wen Chen ^a   De La Pompa, José Luis ^a   McCurrach, Mila E ^b   Shu, Hong Bing ^c   Elia, Andrew J ^a   Shahinian, Arda ^a   Ng, Michelle ^a   Wakeham, Andrew ^a   Khoo, Wilson ^a   Mitchell, Kyran ^d   El Deiry, Wafik S ^d   Lowe, Scott W ^b   Goeddel, David V ^c   Mak, Tak W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; ONCOPROTEIN; PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL BLEEDING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; HEART FAILURE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOXORUBICIN; EMBRYONIC AND FETAL DEVELOPMENT; ENDOTHELIUM, VASCULAR; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; GENE EXPRESSION; GENE TARGETING; HEART; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; ONCOGENES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 7144263731     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5358.1954     Document Type: Article

References (39)

1. S. Nagata, Cell 88, 355 (1997).
2. A. M. Chinnaiyan, K. O'Rourke, M. Tewari, V. M. Dixit, ibid. 81, 505 (1995); M. P. Boldin et al., J. Biol. Chem. 270, 7795 (1995).
3. A. M. Chinnaiyan, K. O'Rourke, M. Tewari, V. M. Dixit, ibid. 81, 505 (1995); M. P. Boldin et al., J. Biol. Chem. 270, 7795 (1995).
4. M. Muzio et al., Cell 85, 817 (1996); M. P. Boldin, T. M. Goncharov, Y. V. Goltsev, D. Wallach, ibid., p. 803.
5. M. Muzio et al., Cell 85, 817 (1996); M. P. Boldin, T. M. Goncharov, Y. V. Goltsev, D. Wallach, ibid., p. 803.
6. H. Hsu, J. Xiong, D. V. Goeddel, ibid. 81,495 (1995).
7. H. Hsu, H.-B. Shu, M.-G. Pan, D. V. Goeddel, ibid. 84, 299 (1996).
8. A. M. Chinnaiyan et al., Science 274, 990 (1996); J. Kitson et al., Nature 384, 372 (1996).
9. A. M. Chinnaiyan et al., Science 274, 990 (1996); J. Kitson et al., Nature 384, 372 (1996).
10. 1 offsprings. PCR, Southern, Northern (RNA), and protein immunoblots were performed according to standard procedures. The mutant phenotype was analyzed in 129/C57BL/6 and 129/CD1 backgrounds; no significant differences were observed.
11. For whole mount in situ hybridization, E8.5 to E10 embryos were fixed and processed according to standard protocols. For radioactive in situ hybridization, E11.5 to E12.5 embryos were isolated and processed as for histological analysis. Hybridization was performed according to standard protocols. The FADD probes used were a 1.3-kb full-length murine FADD cDNA and a 0.8-kb 3′ untranslated region fragment.
12. Embryos were dissected between E9.5 to E11.5, fixed in 4% paraformaldehyde, dehydrated, embedded in wax, sectioned, and processed for hematoxylin and eosin (H&E) staining according to standard protocols.
13. W.-C. Yeh, J. L. de la Pompa, A. J. Elia, T. W. Mak, unpublished data.
14. To examine the development of the vascular endothelium, a mutation in the flk1 gene marked with the lacZ gene (23) was bred to heterozygocity into the FADD mutant background. β-Gal staining was performed according to standard protocols.
15. G. Friedrich and P. Soriano, Genes Dev. 5, 1513 (1991).
16. BrdU (100 μg per gram of body weight) was injected intraperitoneally into pregnant females at E10.5 to E11.5. Females were killed 1 hour after injection, and the embryos were dissected and fixed in 70% ethanol for 2 hours at 4°C, and then processed as for H&E staining. Sections were incubated with a monoclonal antibody to BrdU (Beckton Dickinson) at a 1:10 dilution. Staining was performed as described (24), with a biotinylated secondary antibody against mouse immunoglobulin G and avidin-conjugated peroxidase (Vector Laboratory).
17. +/- ES cell clones and transferred them to CD1 pseudopregnant foster mothers. Chimeric embryos were dissected between E10.5 and E11.5 and stained for β-Gal activity.
18. G. H. Pan et al., Science 276, 111 (1997).
19. 5 cells were plated on each well of a six-well dish a day before treatment. After treatment for 24 hours, cells were trypsinized, all supernatants were collected, and cell viability was determined by trypan blue exclusion and 7-amino-actinomycin D staining (26).
20. A.-O. Hueber et al., Science 278, 1305 (1997); C. Friesen, I. Herr, P. H. Krammer, K. M. Debatin, Nature Med. 2, 574 (1996); C. Friesen, S. Fulda, K. M. Debatin, Leukemia 11, 1833 (1997); M. Muller et al., J. Clin. Invest. 99, 403 (1997).
21. A.-O. Hueber et al., Science 278, 1305 (1997); C. Friesen, I. Herr, P. H. Krammer, K. M. Debatin, Nature Med. 2, 574 (1996); C. Friesen, S. Fulda, K. M. Debatin, Leukemia 11, 1833 (1997); M. Muller et al., J. Clin. Invest. 99, 403 (1997).
22. A.-O. Hueber et al., Science 278, 1305 (1997); C. Friesen, I. Herr, P. H. Krammer, K. M. Debatin, Nature Med. 2, 574 (1996); C. Friesen, S. Fulda, K. M. Debatin, Leukemia 11, 1833 (1997); M. Muller et al., J. Clin. Invest. 99, 403 (1997).
23. A.-O. Hueber et al., Science 278, 1305 (1997); C. Friesen, I. Herr, P. H. Krammer, K. M. Debatin, Nature Med. 2, 574 (1996); C. Friesen, S. Fulda, K. M. Debatin, Leukemia 11, 1833 (1997); M. Muller et al., J. Clin. Invest. 99, 403 (1997).
24. 5 in 500 μl per 12-well plate, in the presence of varying multiplicities of infection (MOIs) of dl250 (E1B-defective adenovirus) (27) or a recombinant c-myc-or lacZ-expressing adenovirus. We constructed c-myc-expressing adenovirus by cloning the full-length human c-myc cDNA into a replication-deficient Ad5 as described for lacZ-expressing adenovirus (28).
25. H. E. Ruley, Nature 304, 602 (1983); S. W. Lowe, H. E. Ruley, T. Jacks, D. E. Housman, Cell 74, 957 (1993); M. E. McCurrach, T. M. Connor, C. M. Knudson, S. J. Korsmeyer, S. W. Lowe, Proc. Natl. Acad. Sci. U.S.A. 94, 2345 (1997).
26. H. E. Ruley, Nature 304, 602 (1983); S. W. Lowe, H. E. Ruley, T. Jacks, D. E. Housman, Cell 74, 957 (1993); M. E. McCurrach, T. M. Connor, C. M. Knudson, S. J. Korsmeyer, S. W. Lowe, Proc. Natl. Acad. Sci. U.S.A. 94, 2345 (1997).
27. H. E. Ruley, Nature 304, 602 (1983); S. W. Lowe, H. E. Ruley, T. Jacks, D. E. Housman, Cell 74, 957 (1993); M. E. McCurrach, T. M. Connor, C. M. Knudson, S. J. Korsmeyer, S. W. Lowe, Proc. Natl. Acad. Sci. U.S.A. 94, 2345 (1997).
28. Generation of E1A- and Ras-expressing MEFs was accomplished by mass infection of early-passage MEFs with E1A 13S- and H-rasV12-expressing retroviral vectors as described (79).
29. M. Adachi et al., Nature Genet. 11, 294 (1995); K. Pfeffer et al., Cell 73, 457 (1993).
30. M. Adachi et al., Nature Genet. 11, 294 (1995); K. Pfeffer et al., Cell 73, 457 (1993).
31. C. Moens, B. R. Stanton, L. F. Parada, J. Rossant, Development 119, 485 (1993).
32. T. P. Yamaguchi, D. J. Dumont, R. A. Conlon, M. L. Breitman, J. Rossant, Dev. Suppl. 118, 489 (1993).
33. Y. Mishina, A. Suzuki, N. Ueno, R. R. Behringer, Genes Dev. 9, 3027 (1995).
34. R. M. Mortensen, D. A. Conner, S. Chao, A. A. Geisterfer-Lowrance, J. G. Seidman, Mol. Cell. Biol. 12, 2391 (1992).
35. I. Schmid, C. H. Uittenbogaart, J. V. Giorgi, Cytometry 15, 12 (1994).
36. E. White and B. Stillman, J. Virol. 61, 426 (1987).
37. W. S. El-Deiry et al., Cell 75, 817 (1993).
38. M. E. McCurrach and S. W. Lowe, unpublished data.
39. We thank V. M. Dixit for DR3 and DR4 vectors and P. H. Krammer for agonistic antibody to Fas; H. Hsu, L.-M. Boucher, and members of T.W.M.'s laboratory for material and instructive discussions; I. del Barco Barrantes and B. Hum for technical assistance; M. Saunders for scientific editing; and I. Ng for administrative support. Supported in part by a grant from the National Cancer Institute of Canada (NCIC) and grant CA13106 from the National Cancer Institute and Medical Research Council of Canada.